Drugs / Dendritic Cell/Tumor Fusion Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00799110 | Aug 2008 → Dec 2024 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Beth Israel Deaconess Medical Center | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dendritic Cell/Tumor Fusion Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00799110 ↗ |
| Known as | DC/tumor fusion vaccine | “DC/tumor fusion vaccine” NCT00799110 ↗ |
| Modality | Vaccine | “This research study is evaluating the effect (good and bad) of a dendritic cell/tumor fusion vaccine in combination with the laboratory made agents GM-CSF and imiquimod on the...” NCT00799110 ↗ |
| Route | Subcutaneous | “Participants assigned to Group 1 will undergo subcutaneous vaccination with the dendritic cell tumor fusion vaccine.” NCT00799110 ↗ |